-
Product Insights
Mitochondrial Myopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Mitochondrial Myopathy - Drugs In Development, 2023’, provides an overview of the Mitochondrial Myopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mitochondrial Myopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) - Drugs In Development, 2023’, provides an overview of the Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Encephalomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Encephalomyelitis - Drugs In Development, 2023’, provides an overview of the Encephalomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Duchenne Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Recessive X Chromosome Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Recessive X Chromosome Disorders - Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bocidelpar Sulfate in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bocidelpar Sulfate in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bocidelpar Sulfate in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SV-101 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SV-101 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SV-101 in Metastatic Breast Cancer Drug Details:SV-101 is under development for non...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HM-15912 in Short Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-15912 in Short Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HM-15912 in Short Bowel Syndrome Drug Details:HM-15912 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ASP-8731
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ASP-8731 Drug Details ASP-8731 is under development for treatment of sickle cell disease. It...